← All trials
NCT00903656
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2009
- Primary completion
- May 1, 2012
- Completion date
- May 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Arbeitsgemeinschaft medikamentoese TumortherapieLead sponsor
- LKH FeldkirchOverall official - principal investigator
- KH Elisabethinen LinzOverall official - principal investigator
- Johannes Kepler UniversityOverall official - principal investigator
- Medical University of GrazOverall official - principal investigator
- GlaxoSmithKlineCollaborator
- Paracelsus Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.